9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Antiplatelet Therapy with Integrated Traditional Chinese and Western Medicine for Use in Myocardial Ischemia-Reperfusion Injury: A Review of Clinical Applications and Mechanisms

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Myocardial ischemia-reperfusion injury (MIRI) is common in patients with acute coronary syndrome (ACS) after PCI treatment, which seriously affects the efficacy of revascularization and hinders the postoperative recovery of patients; therefore, the current study is focused on determining effective methods in the treatment of MIRI. Antiplatelet therapy is a routine treatment for ACS, and its benefits for treating MIRI have been previously verified. With the development of traditional Chinese medicine (TCM), many TCM preparations are widely used in the clinic. Many basic and clinical studies have shown that TCM can be used together with antiplatelet drugs, and the safety and efficacy when TCM is included in the treatment are better than when antiplatelet drugs are used alone. This paper summarizes the current research progress of traditional Chinese medicine and Western medicine in the treatment of MIRI to provide a theoretical basis for further research and clinical treatment.

          Related collections

          Most cited references73

          • Record: found
          • Abstract: not found
          • Article: not found

          2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

              Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel. In this multicenter, double-blind, randomized trial, we compared ticagrelor (180-mg loading dose, 90 mg twice daily thereafter) and clopidogrel (300-to-600-mg loading dose, 75 mg daily thereafter) for the prevention of cardiovascular events in 18,624 patients admitted to the hospital with an acute coronary syndrome, with or without ST-segment elevation. At 12 months, the primary end point--a composite of death from vascular causes, myocardial infarction, or stroke--had occurred in 9.8% of patients receiving ticagrelor as compared with 11.7% of those receiving clopidogrel (hazard ratio, 0.84; 95% confidence interval [CI], 0.77 to 0.92; P<0.001). Predefined hierarchical testing of secondary end points showed significant differences in the rates of other composite end points, as well as myocardial infarction alone (5.8% in the ticagrelor group vs. 6.9% in the clopidogrel group, P=0.005) and death from vascular causes (4.0% vs. 5.1%, P=0.001) but not stroke alone (1.5% vs. 1.3%, P=0.22). The rate of death from any cause was also reduced with ticagrelor (4.5%, vs. 5.9% with clopidogrel; P<0.001). No significant difference in the rates of major bleeding was found between the ticagrelor and clopidogrel groups (11.6% and 11.2%, respectively; P=0.43), but ticagrelor was associated with a higher rate of major bleeding not related to coronary-artery bypass grafting (4.5% vs. 3.8%, P=0.03), including more instances of fatal intracranial bleeding and fewer of fatal bleeding of other types. In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rate of overall major bleeding but with an increase in the rate of non-procedure-related bleeding. (ClinicalTrials.gov number, NCT00391872.) 2009 Massachusetts Medical Society
                Bookmark

                Author and article information

                Contributors
                Journal
                Evid Based Complement Alternat Med
                Evid Based Complement Alternat Med
                ECAM
                Evidence-based Complementary and Alternative Medicine : eCAM
                Hindawi
                1741-427X
                1741-4288
                2021
                20 July 2021
                20 July 2021
                : 2021
                : 7409094
                Affiliations
                1Beijing University of Chinese Medicine, Beijing 100078, China
                2Department of Cardiology, Dong Fang Hospital, Fengtai District, Beijing University of Chinese Medicine, Beijing 100078, China
                Author notes

                Academic Editor: Mei Xue

                Author information
                https://orcid.org/0000-0002-3034-7131
                https://orcid.org/0000-0002-7619-2809
                https://orcid.org/0000-0002-8652-1901
                https://orcid.org/0000-0002-9313-466X
                https://orcid.org/0000-0001-7533-2155
                https://orcid.org/0000-0002-1315-5648
                https://orcid.org/0000-0003-3320-7270
                https://orcid.org/0000-0002-8429-5891
                https://orcid.org/0000-0002-5978-4861
                https://orcid.org/0000-0002-5246-5884
                https://orcid.org/0000-0002-6809-3923
                https://orcid.org/0000-0001-8367-1739
                Article
                10.1155/2021/7409094
                8318772
                34335837
                49c22dd5-34e8-4163-bc96-b4f0d4f8bfca
                Copyright © 2021 Yuxuan Li et al.

                This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 21 April 2021
                : 16 June 2021
                : 3 July 2021
                Funding
                Funded by: National Natural Science Foundation of China
                Award ID: 81803906
                Funded by: Capital's Funds for Health Improvement and Research
                Award ID: 2020-4-4204
                Funded by: Fundamental Research Funds for the Central Universities
                Award ID: 2019-JYB-TD-008
                Categories
                Review Article

                Complementary & Alternative medicine
                Complementary & Alternative medicine

                Comments

                Comment on this article